Pharmacokinetic study of a new formulation of elacridar

Pharmacokinetic study of a new formulation of elacridar - Pharmacokinetic study of a new formulation of elacridar

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON38922

Enrollment

Registered

2013-10-01

Start date

2013-10-25

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gezonde vrijwiliggers na

Interventions

Tablets containing 25 mg of a new elacridar formulation are used. All subjects will receive one single administration of one or multiple tablets(depending on dose level). Starting dose level is 25 m

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Healthy volunteer; 2. Age >=18 years; 3. Able and willing to give written informed consent; 4. Able and willing to undergo blood sampling for pharmacokinetic sampling; 5. Able and willing to swallow and retain oral medication; 6. Willing to comply to the protocol

Exclusion criteria

Exclusion criteria: 1. Any treatment with investigational drugs within two weeks prior to receiving the first dose of investigational treatment;

Design outcomes

Primary

Measure	Time frame
pharmacokinetic properties of a new elacridar formulation	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)